Form 4: Veracyte CCO Sells Shares Under 10b5-1 Plan

Veracyte's Chief Commercial Officer, John Leite, sold 2,808 shares of common stock for $50 per share, as part of a pre-arranged 10b5-1 trading plan.

Summary

• John Leite, the Chief Commercial Officer-CLIA of Veracyte, Inc. (VCYT), reported a transaction involving the company's common stock.
• On November 25, 2025, Mr. Leite disposed of 2,808 shares of common stock.
• The shares were sold at a price of $50 per share, totaling $140,400.
• Following this transaction, Mr. Leite beneficially owns 86,291 shares of Veracyte common stock.
• The transaction was executed pursuant to a Rule 10b5-1 plan, which Mr. Leite adopted on June 9, 2025.

Sentiment

Score: 5

Explanation: The sale of shares by a Chief Commercial Officer is a routine disclosure for an insider transaction. The fact that it was conducted under a Rule 10b5-1 plan suggests it was pre-scheduled and not necessarily indicative of new negative information, thus maintaining a neutral sentiment.

Positives

• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned sale rather than a reaction to new, non-public information.

Negatives

• An insider sale, even if pre-planned, can sometimes be perceived as a slight negative by investors, as it reduces the insider's direct equity stake in the company.

Future Outlook

This filing does not contain any forward-looking statements or guidance regarding the company's future performance or outlook.

Industry Context

This insider transaction is specific to Veracyte, Inc. and its Chief Commercial Officer. It does not provide broader insights into industry trends or competitive landscape.

Stakeholder Impact

• Shareholders: May view the insider sale with slight caution, though the 10b5-1 plan mitigates concerns about opportunistic selling. The impact is generally neutral given the pre-planned nature.

Key Dates

Recommendation

The sale of shares by a Chief Commercial Officer, executed under a pre-arranged Rule 10b5-1 plan, is a routine insider transaction. It does not inherently signal a change in the company's fundamental prospects or warrant an immediate change in investment strategy. Investors should continue to hold and monitor broader company performance and market conditions.

Keywords

VCYT, Veracyte, John Leite, insider trading, Form 4, stock sale, 10b5-1 plan, Chief Commercial Officer